Two years after General Catalyst said it was buying Ohio safety-net hospital Summa Health, executives shed light on how the “transformation” is going.
Vetenskapsnyheter
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as…
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
Trump officials are disregarding the Biden administration's detailed pandemic plans in favor of their own strategy.
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. We’re ASCOmaxxing. Rest…
The Trump administration has released a sweeping proposal to overhaul the bedrock regulation for all federal grants.
A court in Kenya on Friday suspended a U.S. plan to establish a quarantine facility for Americans exposed to a rare type of Ebola virus spreading in northeastern Congo.
Pharma updates from the Pharmalot campus via the Pharmalittle newsletter
Pfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The Readout
State AG alleges UnitedHealthcare claimed some members were sicker to boost its profits.
The growing Ebola outbreak, the unknowns of microdosing GLP-1s, and more health news from Morning Rounds
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Long term, we don’t know what tiny doses of GLP-1s for cosmetic weight loss can do, writes a weight-loss doctor.
Jamie Justice of XPRIZE Healthspan on the most promising research and "purely scammy" treatments in the world of longevity.
The U.S. is taking extraordinary steps to keep Ebola out. But its policies may create risks for Americans infected overseas and discourage volunteers from responding to the outbreak.
Biotech is producing scientific breakthroughs that once seemed impossible. But according to longtime industry executive Jeremy Levin, the institutions that support these advances, from regulators, to investors, and even public…
This week on "The Readout LOUD," longtime biotech exec Jeremy Levin talks about his new book and the industry's strategic turning point. Listen now.
We still have a lot of questions about Trump's MFN deals with pharma companies.
“Infectious disease threats during the World Cup will almost certainly look much more familiar than frightening headlines suggest,” writes Krutika Kuppalli.